Phibro Animal Health Corporation
PAHC
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.6B
$38.25
▼ -0.86%
P/E
16.14
Mkt Cap
$1.6B
52-Wk Range
$28.25–$60.08
52-Week Range
$28.25 - $60.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 3.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated product portfolio addressing multiple animal health and nutrition needs across major livestock species
- Established distribution network through direct sales offices and partnerships with feed manufacturers and integrators
- Specialized manufacturing capabilities for trace minerals and specialty chemical formulations with industrial applications
- Global geographic diversification across six continents reducing market concentration risk
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Rising global demand for animal protein and livestock productivity optimization
Value
Trading at 0.9x Large Cap Pharma peers — a discount despite the growth profile.
Momentum
Hot
+20.4% over 3m
Quality
Stable
High-growth business (27% revenue growth, 34% gross margin). Profitable with strong growth momentum.
Dividend
Modest
1.25% yield
Smart-money signal
Who's buying PAHC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 26, 2026
Reported EPS of $0.85 vs $0.71 consensus (+19.2% surprise). Revenue of $396.7M vs $381.2M expected (+4.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+19.2%
Revenue trend · last 8Q
—
—
+24%
+32%
+39%
+40%
+21%
+5%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q4 26
$273.2M
$260.4M
$309.3M
$347.8M
$378.7M
$363.9M
$373.9M
$396.7M
Margins · last 8Q
Gross
35.6%
Operating
11.1%
Profit
5.5%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Citi · May 14, 2026
vs Industry
How PAHC stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related